A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.
High-Risk Renal Cell Carcinoma Patients Benefit from Everolimus miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Pembrolizumab shows promise in metastatic breast cancer with high tumor mutational burden Disclosures: A research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp. supported the study. Merck Sharp & Dohme provided pembrolizumab, with additional funding provided by AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech and Pfizer. Alva reports a consultant/advisory role with AstraZeneca, Bristol Myers Squibb, Merck and Pfizer; research funding from Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Genentech, Harpoon Therapeutics, Janssen, Merck Sharp & Dohme, Mirati Therapeutics, Progenics, Prometheus and Roche; and travel, accommodations and expenses from Bristol Myers Squibb and Merck. Please see the study for all authors’ relevant financial disclosures.